The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity (full – 2008)http://onlinelibrary.wiley.com/doi/1....200700255/pdf
Taranabant, a novel cannabinoid type 1 receptor inverse agonist (abst – 2008) http://www.ncbi.nlm.nih.gov/pubmed/18821475
Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions (full – 2009)http://www.nature.com/ijo/journal/v3...o2009132a.html
Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin (abst – 2009)http://www.ncbi.nlm.nih.gov/pubmed/18989636
Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression (abst – 2009)http://www.ncbi.nlm.nih.gov/pubmed/19285266
Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist (full – 2010)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2976981/
Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant (full – 2010)http://onlinelibrary.wiley.com/doi/1...9.06549.x/full
A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes (full – 2010) http://onlinelibrary.wiley.com/doi/1...9.01188.x/full
A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study (abst – 2010) http://www.nature.com/ijo/journal/v3...jo201021a.html
Randomized, controlled, double-blind trial of taranabant for smoking cessation (abst – 2010) http://www.ncbi.nlm.nih.gov/pubmed/20191360
Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans (abst – 2010)http://www.ncbi.nlm.nih.gov/pubmed/20722472
Neuropsychiatric adverse effects of centrally acting antiobesity drugs (abst – 2011) http://www.ncbi.nlm.nih.gov/pubmed/21951371
Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22722508
The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice (abst – 2013)http://www.ncbi.nlm.nih.gov/pubmed/23692073
Development of amorphous solid dispersion formulations of a poorly water-soluble drug, MK-0364 (abst – 2013)http://www.ncbi.nlm.nih.gov/pubmed/23651642
Taranabant, a novel cannabinoid type 1 receptor inverse agonist (abst – 2008) http://www.ncbi.nlm.nih.gov/pubmed/18821475
Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions (full – 2009)http://www.nature.com/ijo/journal/v3...o2009132a.html
Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin (abst – 2009)http://www.ncbi.nlm.nih.gov/pubmed/18989636
Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression (abst – 2009)http://www.ncbi.nlm.nih.gov/pubmed/19285266
Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist (full – 2010)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2976981/
Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant (full – 2010)http://onlinelibrary.wiley.com/doi/1...9.06549.x/full
A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes (full – 2010) http://onlinelibrary.wiley.com/doi/1...9.01188.x/full
A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study (abst – 2010) http://www.nature.com/ijo/journal/v3...jo201021a.html
Randomized, controlled, double-blind trial of taranabant for smoking cessation (abst – 2010) http://www.ncbi.nlm.nih.gov/pubmed/20191360
Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans (abst – 2010)http://www.ncbi.nlm.nih.gov/pubmed/20722472
Neuropsychiatric adverse effects of centrally acting antiobesity drugs (abst – 2011) http://www.ncbi.nlm.nih.gov/pubmed/21951371
Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22722508
The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice (abst – 2013)http://www.ncbi.nlm.nih.gov/pubmed/23692073
Development of amorphous solid dispersion formulations of a poorly water-soluble drug, MK-0364 (abst – 2013)http://www.ncbi.nlm.nih.gov/pubmed/23651642